<DOC>
	<DOCNO>NCT02820155</DOCNO>
	<brief_summary>This double-blind , randomize , placebo-controlled , dose-escalating , single dose multiple dose study .</brief_summary>
	<brief_title>Phase I Single Multiple Escalating Dose Study RGN1016 Healthy Male Subjects</brief_title>
	<detailed_description>This double-blind , randomize , placebo-controlled , dose-escalating study . The study comprise single dose ( Stage I ) multiple dose ( Stage II ) stage . Stage II initiate completion Stage I . The interim safety analysis report submit TFDA approval proceed Stage II .</detailed_description>
	<criteria>Subjects may enter study meet follow criterion : 1 . Male suitable vein cannulation repeat venipuncture , must able swallow study drug intact ; 2 . Aged 20 45 year ( inclusive ) screen visit ; 3 . Has normal hematology result screen visit ; WBC : 3.54 ~ 9.06X10^3/μL RBC : 4 ~ 5.52X10^6/μL hemoglobin : 13.2 ~17.2 g/dL hematocrit : 40.4 ~ 51.1 % platelet : 148 ~ 339X10^3/μL 4 . Has normal biochemistry result screen visit ; alkaline phosphatase : 34 ~ 104 U/L total bilirubin : 0.3 ~ 1.0 mg/dL AST : 8 ~ 31 U/L ALT : 0 ~ 41 U/L BUN : 7 ~ 25 mg/dL creatinine : 0.6 ~ 1.3 mg/dL 5 . Normal coagulation result screen visit ; Prothrombin time/INR : 9.8 ~ 11.5 sec/0.92 ~ 1.09 PTT : 25.6~32.6 sec 6 . Normal blood pressure ( systolic blood pressure : 100 ~ 140 mmHg ; diastolic blood pressure : 60 ~ 90 mmHg ) screen visit prior administration investigational product ; 7 . Able provide write informed consent willing comply study protocol procedure restriction . Subjects must satisfy follow criterion : 1 . Has body weight less 50 kg and/or body mass index ( BMI ) less 18 kg/m^2 great 30 kg/m^2 screen visit . Body mass index determine total body weight/height^2 ( kg/m^2 ) ; 2 . Is good general health judge Investigator base medical history , vital sign , physical examination , ECG , laboratory test , urinalysis screen visit prior administration investigational product ; 3 . Has history presence disease condition know interfere absorption , distribution , metabolism , excretion drug screen visit prior administration investigational product ; 4 . Has clinically significant psychiatric , renal , hepatic , cardiovascular , gastrointestinal , neurologic disease screen prior administration investigational product ; 5 . Is smoker and/or use nicotinecontaining product within last 6 month prior screen visit ; 6 . Has history alcohol and/or drug abuse ; 7 . Participation clinical investigation last 60 day ; 8 . Blood donation 250 mL within past 12 week ; 9 . Excessive intake caffeine contain drink food ( 6 unit caffeine per day ) . One caffeine unit contain follow item : 1 ( 177.4 mL ) cup coffee , 2 ( 354.9 mL ) can cola , 1 ( 354.9 mL ) cup tea , ½ ( 118.3 mL ) cup energy drink ( e.g. , PAOLYTA B Liq . WHISBIH Liq . ) 3 oz chocolate ; 10 . Use drug enzyme induce property St. John 's Wort within 4 week prior dose ; 11 . Has use prescription nonprescription medication ( except occasional use paracetamol nasal spray ) herbal remedy vitamins mineral within 2 week 5 halflives drug , whichever longer , prior dosing ; 12 . Any intake grapefruit , grapefruit juice , Seville oranges , Seville orange marmalade , product contain grapefruit Seville oranges within 7 day first administration study medication ; 13 . Male subject unwilling use barrier contraception addition partner use another method contraception , duration study 3 month dose ; 14 . Has positive result screen serum hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody ( HCV Ab ) , human immunodeficiency virus ( HIV ) ; 15 . Has receive blood transfusion within last 6 month screen ; 16 . Involved plan conduct study .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Alzheimer 's disease , cognitive function</keyword>
</DOC>